Search

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

The glamorous life of parenthood and medicine

The glamorous life of parenthood and medicine

By Ana Zelić Kerep, MD (YoungEHA Ambassador)

Is it possible to have it all – the career, the family, good health, and sanity? Is it possible to give all of yourself to work and still…

Read more

Current status of the Clinical Trials Regulation

HemAffairs Article #2 – June 2019

In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.

Read more

Expert opinions for COVID-19 vaccination in patients with hematologic cancer

Ronja Brockhoff, Hamdi Akan, Rafael Duarte, Martin Hönigl, Nikolay Klimko, Sibylle C. Mellinghoff, Livio Pagano, Antonio Pagliuca, Paul Verweij, Oliver A.

Read more

Substances of Human Origin (SoHO) legislation

EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.

Read more

Enabling the spread of good research – a day in the life of an Editor-in-Chief

Most conversations with the Editor of a scientific journal usually revolve around the acceptance (hooray!) or rejection (oh no!) of our research work.

Read more

Key messages of the 22nd Congress of EHA brought to the Middle East and North Africa

The second edition of the Highlights of Past EHA (HOPE) brought the key messages of the 22nd Congress of EHA to the Cairo, Egypt in September 2017.

Read more

EuroBloodNet aims for better care for patients with rare blood disorders

ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more

100,000 Patient data sets: The value of data sharing to accelerate blood cancer research.

With almost 100,000 patient data sets identified and 63,000 already transferred to the HARMONY Big Data Platform, the HARMONY Alliance is fully equipped to facilitate state-of-the-art research into blood cancers.

Read more